Advertisement
Home »

Pharmacokinetic Properties of a Once-Weekly Fixed-Ratio Combination of Insulin Icodec and Semaglutide Compared with Separate Administration of Each Component in Individuals with Type 2 Diabetes Mellitus.

Nov 04, 2024

ABOUT THE EXPERTS

  • Lisbet Westergaard

    Novo Nordisk, Development, Søborg, Denmark.

    Lene Alifrangis

    Novo Nordisk, Research and Early Development, Måløv, Denmark.

    Stephen T Buckley

    Novo Nordisk, Research and Early Development, Måløv, Denmark.

    Hans Veit Coester

    Profil, Neuss, Germany.

    Thomas Klitgaard

    Novo Nordisk, Research and Early Development, Måløv, Denmark.

    Niels R Kristensen

    Novo Nordisk, Development, Søborg, Denmark.

    Erica Nishimura

    Novo Nordisk, Research and Early Development, Måløv, Denmark.

    Lea Nørgreen

    Novo Nordisk, Development, Aalborg, Denmark.

    Thaís M P Rocha

    Novo Nordisk, Development, Søborg, Denmark.

    Dorte B Steensgaard

    Novo Nordisk, Research and Early Development, Måløv, Denmark.

    Andreas Vegge

    Novo Nordisk, Research and Early Development, Måløv, Denmark.

    Leona Plum-Mörschel

    Profil, Neuss, Germany. leona.plum-moerschel@profil.com.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement